U.S., Nov. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07246304) titled 'TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC' on Nov. 17.
Brief Summary: This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of TC-D101 CAR-T cells in patients with DLL3-positive Relapsed/Refractory primary small cell lung cancer(r/r SCLC) who have progressed after prior therapies. The primary objective is to determine the maximum tolerated dose (MTD), with a secondary aim to assess preliminary clinical efficacy in SCLC.
Study Start Date: Nov. 30
Study Type: INTERVENTIONAL
Condition:
Small Cell Lung Cancer ( SCLC )
CAR-T Cell Ther...